When should Rexulti (brexpiprazole) be administered?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 11, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

When Should Rexulti Be Taken?

Rexulti (brexpiprazole) should be administered once daily, either with or without food, as timing relative to meals does not affect its absorption or efficacy. 1

Dosing Schedule

  • Administer brexpiprazole orally once daily at any time of day 1
  • Food does not impact administration - the medication can be taken with or without food based on patient preference 1
  • Consistency in timing is recommended - while not explicitly required by the FDA label, taking the medication at the same time each day helps maintain steady plasma levels and improves adherence 1

Titration Requirements

The medication requires gradual dose escalation to reach target doses:

  • For Major Depressive Disorder (MDD): Start at 0.5-1 mg/day, titrate to target dose of 2 mg/day (maximum 3 mg/day) 1
  • For Schizophrenia: Start at 1 mg/day, titrate to target dose of 2-4 mg/day (maximum 4 mg/day) 1
  • Titration should occur over 1-2 weeks to reach the target therapeutic dose 2

Pharmacokinetic Considerations

  • Time to peak concentration (tmax) occurs at 4-5 hours after administration 3
  • Steady-state is achieved after approximately 10 days of consistent daily dosing 3
  • Elimination half-life is 52-92 hours, supporting once-daily dosing and providing flexibility in timing 3
  • Accumulation occurs over 2.5- to 5.5-fold by day 14 compared to initial dosing, which is why gradual titration is necessary 3

Special Population Adjustments

  • Moderate to severe hepatic impairment: Maximum 2 mg/day for MDD, 3 mg/day for schizophrenia 1
  • Renal impairment (CrCl <60 mL/min): Maximum 2 mg/day for MDD, 3 mg/day for schizophrenia 1
  • CYP2D6 poor metabolizers: Dose adjustments required due to higher drug exposure 1, 3

Clinical Pearls

  • No specific time-of-day advantage - unlike some antipsychotics that cause sedation (requiring bedtime dosing) or activation (requiring morning dosing), brexpiprazole demonstrates a balanced profile with relatively low incidence of both activating and sedating effects 4
  • Akathisia monitoring is most relevant during dose titration, occurring in 5.5% of schizophrenia patients and 8.6% of MDD patients, but timing of administration does not mitigate this risk 5
  • Do not abruptly discontinue - if stopping brexpiprazole, consider gradual tapering (approximately 10% per week) to minimize withdrawal symptoms, though this is more critical when switching to other antipsychotics 6

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.